Allergan PLC issued 2017 guidance Thursday saying that the company expects to deliver non-GAAP mid-single-digit top-line net revenue growth. The growth is assumed based on stable net revenue for Restasis, a medication for chronic dry eye and a combination of the launch of Namenda XR, an Alzheimer’s medication, in the fourth quarter of 2017, offset by strong performance from Namzaric, another Alzheimer’s medication. It does not including the company’s acquisition of Lifecell. Allergan said it expects to reach double-digit non-GAAP earnings per share growth in 2017. Analysts surveyed by FactSet expected earnings per share of $16.08 and sales of $15.3 billion for 2017. Shares of Allergan were up less than 1% Thursday morning. Shares of Allergan have gained 13% in the past month compared to the S&P 500’s gain of 3%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News